Zacks: Analysts Set $2.83 Price Target for Xtant Medical Holdings Inc (XTNT)
Shares of Xtant Medical Holdings Inc (NASDAQ:XTNT) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.
Brokerages have set a 12-month consensus target price of $2.83 for the company and are anticipating that the company will post ($0.13) earnings per share for the current quarter, according to Zacks. Zacks has also given Xtant Medical Holdings an industry rank of 82 out of 265 based on the ratings given to related companies.
A number of analysts recently issued reports on the stock. Aegis assumed coverage on shares of Xtant Medical Holdings in a report on Wednesday, November 30th. They set a “buy” rating and a $3.50 price target on the stock. Zacks Investment Research downgraded shares of Xtant Medical Holdings from a “buy” rating to a “hold” rating in a report on Saturday, January 7th. Finally, Maxim Group assumed coverage on shares of Xtant Medical Holdings in a report on Thursday, December 8th. They set a “buy” rating and a $2.00 price target on the stock.
Shares of Xtant Medical Holdings (NASDAQ:XTNT) opened at 0.5829 on Monday. The stock has a 50 day moving average of $0.56 and a 200-day moving average of $1.11. The company’s market capitalization is $7.11 million. Xtant Medical Holdings has a 12-month low of $0.45 and a 12-month high of $3.75.
Xtant Medical Holdings Company Profile
Xtant Medical Holdings, Inc, formerly Bacterin International Holdings, Inc, develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The Company operates through the development, manufacture and marketing of regenerative medical products and devices segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xtant Medical Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xtant Medical Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.